Cardioprotection
Phase 2Small molecule
Cardioprotection is one of 20 small molecule programs targeting CAR. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in CAR
#DrugCompanyPhaseTrials
1Isopto Carpine
AAdvanz Pharma
Phase 3
Floxin
WWim Janssens
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
L-Carnitine
IIperboreal Pharma Srl
Phase 3
Tegretol
NovartisPhase 1
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Diamox
TevaPhase 1
Trileptal
NovartisPreclinical
Cardene
Sun Pharmaceutical Industries, Inc.Preclinical
Dobutrex
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
CAR1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cardioprotection. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Virginia